Interferon-liposomes prepared to make macroglia maintain M1 phenotype

doi:10.5246/jcps.2019.07.046

Abstract

Abstract:

Macroglia is a crucial macrophage only existing in the central nervous system. During the development of glioma, it can be activated as M2 anti-inflammatory type to promote glioma growth. Interferon-γ (IFN-γ) is an important immunomodulator inglioma microenvironment, which can also activate macroglia as M1 pro-inflammatory type to enhance anti-tumor immune responseand lead to inhibition of glioma growth. Therefore, we utilized IFN-γ to make macroglia maintain M1 phenotype, so that prospectively achieving anti-tumor immunity for glioma therapy. We prepared interferon-γ-liposomes (IFN-Lp) to protect IFN-γ from elimination. IFN-Lp was proved to have strong capability to be phagocytosed and accumulate in macroglia (BV2 cells) to achieve long-term effect. In addition, IFN-Lp could allow BV2 cells to maintain M1 phenotype, showing no impact on its cell viability. These findings will offer new opportunities to achieve enhanced immunotherapy of glioma.

Key words: Interferon-γ, Liposomes, Microglia, Drug delivery

CLC Number:

R943

Supporting:

Yitian Du, Lu Zhang, Yin Zhan, Xinyu Chai, Kaisen Li, Xianrong Qi. Interferon-liposomes prepared to make macroglia maintain M1 phenotype[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(7): 476-483.

References

[1] Leitinger, N.; Schulman, I.G. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1120-1126.

[2] da Fonseca, A.C.; Badie, B. Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin. Dev. Immunol. 2013, 2013, 264124.

[3] Komohara, Y.; Ohnishi, K.; Kuratsu, J.; Takeya, M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216, 15-24.

[4] Gabrusiewicz, K.; Ellert-Miklaszewska, A.; Lipko, M.; Sielska, M.; Frankowska, M.; Kaminska, B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One. 2011, 6, e23902.

[5] Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549-555.

[6] Sica, A.; Schioppa, T.; Mantovani, A.; Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer. 2006, 42, 717-727.

[7] Jones, L.M.; Broz, M.L.; Ranger, J.J.; Ozcelik, J.; Ahn, R.; Zuo, D.M.; Ursini-Siegel, J.; Hallett, M.T.; Krummel, M.; Muller, W.J. STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res. 2016, 76, 1416-1428.

[8] Ellert-Miklaszewska, A.; Dabrowski, M.; Lipko, M.; Sliwa, M.; Maleszewska, M.; Kaminska, B. Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia. 2013, 61, 1178-1190.

[9] Takeda, K.; Akira, S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000, 11, 199-207.

[10] Mills, C.D.; Kincaid, K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. M-1/M-2 macrophages and the th1/th2 paradigm. J. Immunol. 2000, 164, 6166-6173.

[11] Pestka, S.; Krause, C.D.; Walter, M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202, 8-32.

[12] Wall, L.; Burke, F.; Barton, C.; Smyth, J.; Balkwill, F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin. Cancer Res. 2003, 9, 2487-2496.

[13] Zhang, J.W. Yin and Yang interplay of IFN-γ in inflammation and autoimmune disease. J. Clin. Invest. 2007, 117, 871-873.

[14] Boehm, U.; Klamp, T.; Groot, M.; Howard, J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 1997, 15, 749-795.

[15] Schroder, K.; Hertzog, P.J.; Ravasi, T.; Hume, D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75, 163-189.

[16] Durbin, J.E.; Hackenmiller, R.; Simon, M.C.; Levy, D.E. Targeted disruption of the mouse stat1 gene results in compromised innate immunity to viral disease. Cell. 1996, 84, 443-450.

[17] Elliott, M.R.; Koster, K.M.; Murphy, P.S. Efferocytosis signaling in the regulation of macrophage inflammatory responses. J. Immunol. 2017, 198, 1387-1394.

[18] van Slooten, M.L.; Boerman, O.; Romøren, K.; Kedar, E.; Crommelin, D.J.A.; Storm, G. Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspects. Biochim. Et Biophys. Acta Bba - Mol. Cell Biol. Lipids. 2001, 1530, 134-145.

[19] Song, Q.L.; Yin, Y.J.; Shang, L.H.; Wu, T.T.; Zhang, D.; Kong, M.; Zhao, Y.D.; He, Y.Z.; Tan, S.W.; Guo, Y.Y.; Zhang, Z.P. Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy. Nano Lett. 2017, 17, 6366-6375.

[20] Mäger, I.; Langel, K.; Lehto, T.; Eiríksdóttir, E.; Langel, U. The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. Biochim. Biophys. Acta. 2012, 1818, 502-511.

[21] Herd, H.; Daum, N.; Jones, A.T.; Huwer, H.; Ghandehari, H.; Lehr, C.M. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano. 2013, 7, 1961-1973.

[22] Bhowmick, T.; Berk, E.; Cui, X.M.; Muzykantov, V.R.; Muro, S. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J. Control. Release. 2012, 157, 485-492.

[23] Sato, K.; Mitsui, N.; Ryoko Yumoto,, Takano, M. Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells. Life Sci. 2009, 85, 800-807.

[24] Schulz, W.L.; Haj, A.K.; Schiff, L.A. Reovirus uses multiple endocytic pathways for cell entry. J. Virol. 2012, 86, 12665-12675.

[25] Hu, X., K.H. Park-Min, H.H. Ho, and L.B. Ivashkiv, IFN-Gamma-Primed Macrophages Exhibit Increased CCR2-Dependent Migration and Altered IFN-Gamma Responses Mediated by Stat1. J. Immunol. 2005. 175, 3637-3647.

[25] Hu, X.Y.; Park-Min, K.H.; Ho, H.H.; Ivashkiv, L.B. IFN-gamma-primed macrophages exhibit increased CCR2-dependent migration and altered IFN-gamma responses mediated by Stat1. J. Immunol. 2005, 175, 3637-3647.

[26] Cieslewicz, M.; Tang, J.J.; Yu, J.L.; Cao, H.; Zavaljevski, M.; Motoyama, K.; Lieber, A.; Raines, E.W.; Pun, S.H. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc. Natl. Acad. Sci. USA. 2013, 110, 15919-15924.